quality of life

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do...

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.  Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.  The bicaval...

Claudicación Intermitente: ¿el tratamiento invasivo es superior al tratamiento farmacológico?

Intermittent Claudication: Invasive Treatment Superior to Pharmacological Treatment?

Peripheral vascular disease is strongly associated to cardiovascular events and a negative impact on health status and quality of life.  However, researchers are yet to determine the benefit of early intervention in patients presenting intermittent claudication, and whether it improves quality of life.  At present, there is little information in this regard (CLEVER trial), and...

¡Gracias a todos por ser parte de las Jornadas SOLACI Paraguay 2022!

Thanks everyone for making part of Paraguay SOLACI Sessions 2022!

We have reached the end of SOLACI Sessions 44th edition.  We have enjoyed 2 days of intense scientific activities with multiple educational symposia, case study discussions, theoretical and practical approaches to issues of interest in interventional cardiology and fruitful knowledge exchange between prestigious colleagues from Paraguay and Latin America.  With over 200 registered attendees and...

El Grupo MIL realizó 4 TAVIS en Paraguay

The Latin American Group of Interventionist Women Performed 4 TAVR Cases in Paraguay

The MIL-SOLACI continues to grow and keeps developing activities to foster integration and women’s participation all across Latin America.  IN this opportunity, and for the first time, the area directed by Dr. Carla Agatiello (ARG) performed 4 transcatheter aortic valve implantations (TAVR) at the National University’s Clinical Hospital of Asunción, in Paraguay.  The interventions, performed...

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular...

La enfermedad vascular periférica se asocia a más eventos en el TAVI

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving...

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | TriCLASP, Evolution at 30 Days

Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.  Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients...

Top